ABSTRACT
Mycoplasma hominis, a common coloniser of the urogenital tract, is a rare cause of respiratory infections in an immunocompetent patient. M. hominis lacks a cell wall and can be difficult to identify with standard culture methods posing difficulties in diagnosis and treatment. We describe a case of M. hominis pneumonia in an immunocompetent man in his early 40s without any risk factors presenting with a cavitary lesion who developed empyema and necrotising pneumonia requiring surgical debridement. Identification of M. hominis and subsequent modification of antibiotic therapy led to favourable outcome. M. hominis should be considered in the differential diagnosis of patients with treatment resistant pneumonia especially in patients with trauma, intracranial injury, lung transplant or if immunocompromised. While M. Hominis is naturally resistant to all antibiotics that target cell wall synthesis, we recommend levofloxacin or other fluoroquinolone to most effectively treat with doxycycline as a potential alternative.
Subject(s)
Mycoplasma Infections , Pneumonia, Necrotizing , Pneumonia , Humans , Male , Adult , Mycoplasma hominis , Mycoplasma Infections/complications , Mycoplasma Infections/diagnosis , Mycoplasma Infections/drug therapy , Pneumonia, Necrotizing/drug therapy , Anti-Bacterial Agents/therapeutic use , Pneumonia/drug therapyABSTRACT
Background: Immune checkpoint inhibitors (ICIs) are a promising new treatment for different types of cancer. The infectious complications in patients taking ICIs are rare. Case report: A 58-year-old male who received chemotherapy consisting of pembrolizumab (PD-1 inhibitor) for esophagus squamous cell carcinoma one month before was admitted to the emergency room with shortness of breath soon after fiberoptic bronchoscopy, which was done for the inspection of the lower airway. A computed tomography of the chest revealed a progressive consolidation on the right upper lobe. Salmonella group D was isolated from the bronchoalveolar lavage (BAL) fluid culture. The fungal culture of the same clinical sample yielded Aspergillus niger; furthermore, a high titer (above the cut-off values) of Aspergillus antigen was found both in the BAL fluid and serum of the patient. Despite the effective spectrum and appropriate dose of antimicrobial treatment, the patient died due to disseminated intravascular coagulopathy. Conclusions: Awareness of unusual pathogens in the etiology of pneumonia after ICI treatment may help to avoid underdiagnosis.(AU)
Antecedentes: Los fármacos inhibidores de puntos de control inmunitario (ICI) son una nueva y prometedora opción de tratamiento para diferentes tipos de cáncer. Las complicaciones infecciosas en pacientes que toman ICI son poco frecuentes. Caso clínico: Un varón de 58 años que recibió quimioterapia con pembrolizumab (inhibidor de PD-1) para un carcinoma de células escamosas de esófago hacía un año, ingresó en Urgencias por dificultad respiratoria poco después de realizarse una broncoscopia de fibra óptica para una inspección de las vías aéreas inferiores. La tomografía computarizada de tórax reveló una consolidación progresiva en el lóbulo superior derecho. Se aisló Salmonella grupo D en el cultivo del líquido de lavado broncoalveolar (LBA). En el cultivo de hongos de la misma muestra creció Aspergillus niger; además, se detectó antígeno (por encima de los valores de corte) de Aspergillus tanto en la muestra del LBA como en el suero del paciente. A pesar del espectro eficaz y la dosis adecuada del antifúngico utilizado, el paciente falleció debido a una coagulopatía intravascular diseminada. Conclusiones: El conocimiento de patógenos inusuales en la etiología de la neumonía tras el tratamiento con ICI puede ayudar a evitar el infradiagnóstico.(AU)
Subject(s)
Humans , Male , Middle Aged , Pneumonia, Necrotizing/drug therapy , Esophageal Neoplasms/drug therapy , /drug therapy , Typhoid Fever , Invasive Pulmonary Aspergillosis , Inpatients , Physical Examination , Mycology , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/microbiology , SalmonellaABSTRACT
BACKGROUND: Necrotizing pneumonia is rare in children and is one of the most serious complications of a lung infection caused by antibiotic failure. We present a 12-year-old leukopenic child with a long-lasting lung infection, presenting as having a lung hydatid cyst, but diagnosing with necrotizing pneumonia in the right bilobed lung. Failure to medical treatment and ongoing leukopenia justified surgical intervention with positive results. CASE PRESENTATION: The patient was referred to our teaching hospital's pediatric surgery department. He had previously been diagnosed with intestinal tuberculosis (TB) and received anti-TB treatment. On referral to our hospital, the patient was suffering from restlessness, frequent coughing, fever, vomiting, and diarrhea. Following the completion of the clinical work-up, a blood test revealed leukopenia (white blood cell count of 2100/microliter), a normal platelet count, and a lesion in the right lung. Computerized tomography scanning (CT-Scan) image reported a lung hydatid cyst. In the pediatrics ward, a broad-spectrum antibiotics regimen with triple-antibiotic therapy (linezolid, vancomycin, and metronidazole) was instituted and continued for a week with no response, but worsening of the condition. In the pediatric surgery ward, our decision for surgical intervention was due to the failure of medical treatment because of a pulmonary lesion. Our team performed right lung upper lobe anterior segment wedge resection due to necrotizing pneumonia and followed the patient 45 days post-operation with a reasonable result. CONCLUSION: Living in remote rural areas with low resources and inaccessibility to proper and specialized diagnostic and treatment centers will all contribute to an improper diagnosis and treatment of lung infection. In total, all of these will increase the morbidity and mortality due to lung necrosis in the pediatric population, regardless of their age. In low-resource facilities, high-risk patients can benefit from surgical intervention to control the ongoing infection process.
Subject(s)
Echinococcosis , Leukopenia , Pneumonia, Necrotizing , Pneumonia , Male , Child , Humans , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/surgery , Pneumonia, Necrotizing/drug therapy , Lung/diagnostic imaging , Lung/surgery , Lung/pathology , Pneumonia/diagnosis , Pneumonia/etiology , Pneumonia/drug therapy , Anti-Bacterial Agents/therapeutic use , Echinococcosis/drug therapy , Echinococcosis/pathologySubject(s)
Pneumonia, Necrotizing , Pneumonia, Staphylococcal , Staphylococcal Infections , Humans , Staphylococcus aureus , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/drug therapy , Leukocidins , Exotoxins , Pneumonia, Staphylococcal/diagnosis , Pneumonia, Staphylococcal/drug therapy , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapySubject(s)
COVID-19 , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Necrotizing , Sepsis , Staphylococcal Infections , Vascular Diseases , Humans , Infant , Staphylococcus aureus , Methicillin , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/drug therapy , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Catheters , Anti-Bacterial Agents/therapeutic useABSTRACT
Rhodococcus hoagii is a well-known zoonotic disease, especially in foals. Its occurrence in humans is uncommon and usually occurs in immunocompromised patients. We present a case of Rhodococcus hoagii infection resulting in necrotizing pneumonia in a patient with advanced retroviral disease who had defaulted treatment. Effective treatment of Rhodococcus hoagii infection requires a combination of antibiotics. We also highlighted the importance of effective communication between clinicians and microbiologists so that prompt treatment can be initiated to improve patient outcomes.
Subject(s)
Pneumonia, Necrotizing , Rhodococcus equi , Animals , Humans , Horses , Pneumonia, Necrotizing/drug therapy , Anti-Bacterial Agents/therapeutic useABSTRACT
Background: Necrotizing pneumonia rarely occurs in children, but when it does it can be complicated by bronchopleural fistula, empyema, pneumothorax, sepsis, and acute respiratory distress syndrome (ARDS). Antimicrobial therapy is the cornerstone of its management; however, surgery is necessary in some cases. Ideally, surgical interventions are kept to a minimum, but this is not always possible if there is a mass effect from air and fluid in the pleural space, pulmonary necrosis leading to massive hemoptysis, uncontrolled sepsis, or difficulties with assisted ventilation. Case Presentation: Herein we present a patient with refractory pyopneumothorax and ARDS due to pneumococcal necrotizing pneumonia complicated by a bronchopleural fistula. The patient's clinical condition deteriorated despite antibiotics, surgical drainage, and assisted ventilation. Owing to pneumothorax with a high percentage of air leakage, bilateral diffuse collapse of the lungs, and insufficient oxygenation, surgical treatment was considered, but because of the patient's lack of tolerance for surgery due to hemodynamic reasons and the complications associated with surgery, medical treatment was determined to be more appropriate. Surfactant treatment was administered to the patient, resulting in significant clinical improvement. Conclusion: To the best of our knowledge, this is the first report of the use of surfactant to treat ARDS due to necrotizing pneumonia. Based on the presented case, we think surfactant can be considered as a salvage treatment for such patients.
Subject(s)
Bronchial Fistula , Empyema, Pleural , Pleural Diseases , Pneumonia, Necrotizing , Pneumonia, Pneumococcal , Pneumothorax , Respiratory Distress Syndrome , Sepsis , Anti-Bacterial Agents/therapeutic use , Bronchial Fistula/complications , Bronchial Fistula/surgery , Child , Empyema, Pleural/complications , Empyema, Pleural/drug therapy , Humans , Pleural Diseases/complications , Pleural Diseases/drug therapy , Pneumonia, Necrotizing/complications , Pneumonia, Necrotizing/drug therapy , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/drug therapy , Pneumothorax/complications , Pneumothorax/drug therapy , Respiratory Distress Syndrome/complications , Respiratory Distress Syndrome/drug therapy , Sepsis/complications , Sepsis/drug therapy , Streptococcus pneumoniae , Surface-Active AgentsABSTRACT
BACKGROUND: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a common pathogen that usually causes bacteraemia, osteomyelitis, as well as skin and soft tissue infections. However, deep venous thrombosis (DVT) and necrotising pneumonia are rare in infants. CASE PRESENTATION: We report the case of a one-month-five-day-old girl who was hospitalised for DVT and necrotising pneumonia due to septicaemia associated with Staphylococcus aureus. She recovered after treatment with intravenous antibiotics and multiple anticoagulant therapy, but DVT persisted at the three-year follow-up. Collateral circulation around the DVT was well-formed. Post thrombotic syndrome was not observed. CONCLUSIONS: Staphylococcus aureus complicated by DVT and necrotising pneumonia is rare and can be successfully treated.
Subject(s)
Community-Acquired Infections , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Necrotizing , Sepsis , Staphylococcal Infections , Venous Thrombosis , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/complications , Community-Acquired Infections/drug therapy , Female , Humans , Infant , Pneumonia, Necrotizing/complications , Pneumonia, Necrotizing/drug therapy , Sepsis/drug therapy , Staphylococcal Infections/complications , Staphylococcal Infections/drug therapy , Venous Thrombosis/etiologySubject(s)
Community-Acquired Infections , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Necrotizing , Staphylococcal Infections , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Exotoxins , Humans , Infant , Leukocidins , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/drug therapy , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapyABSTRACT
BACKGROUND: Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with less than half of exposures progressing to a symptomatic state that primarily consists of pulmonary manifestations. Disseminated coccidioidomycosis is exceedingly rare, occurring in fewer than 1 % of symptomatic infections. Through hematogenous spread, the fungus can infect most organ systems and may be fatal without systemic antifungal treatment. Individuals with impaired cell-mediated immunity either from primary immunodeficiency disorders or secondary to immunosuppression with medications such as tumor necrosis factor alpha (TNF-α) inhibitors have increased risk of disseminated coccidioidomycosis and previous cases of coccidioidomycosis have been reported with biologic therapy. CASE PRESENTATION: We present a case of disseminated coccidioidomycosis in a 16-year-old female with polyarticular juvenile idiopathic arthritis (JIA) being treated with prednisone, methotrexate, and infliximab. The patient presented with symptoms of meningeal irritation, bilateral choroidal lesions, and necrotizing peripheral pneumonia. Her infection was thought to be a reactivation of coccidioidomycosis given her history of resolved pneumonia that occurred after traveling to Arizona, New Mexico, and El Paso one year prior to presentation. Following diagnosis, she improved with discontinuation of her immunosuppressive medications and two weeks of intravenous amphotericin B and fluconazole with plans for lifetime treatment with fluconazole while immunosuppressed. Due to worsening arthritis, she will begin tofacitinib and continue close monitoring of chest x-rays and coccidioides antibody. CONCLUSIONS: Patients undergoing immunosuppressive therapy for rheumatological conditions are at increased risk of disseminated coccidioidomycosis and should be evaluated with high suspicion when presenting with atypical symptoms and history of travel to endemic regions.
Subject(s)
Amphotericin B/administration & dosage , Arthritis, Juvenile , Choroid Diseases , Coccidioides , Coccidioidomycosis , Fluconazole/administration & dosage , Meningitis, Fungal , Pneumonia, Necrotizing , Adolescent , Antifungal Agents/administration & dosage , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Antirheumatic Agents/classification , Antirheumatic Agents/immunology , Arthritis/drug therapy , Arthritis/immunology , Arthritis, Juvenile/drug therapy , Arthritis, Juvenile/immunology , Choroid Diseases/diagnosis , Choroid Diseases/drug therapy , Coccidioides/immunology , Coccidioides/isolation & purification , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Coccidioidomycosis/immunology , Coccidioidomycosis/physiopathology , Disease Progression , Female , Humans , Immune Tolerance/drug effects , Immune Tolerance/immunology , Infliximab/administration & dosage , Infliximab/adverse effects , Infliximab/immunology , Meningitis, Fungal/diagnosis , Meningitis, Fungal/drug therapy , Meningitis, Fungal/microbiology , Monitoring, Immunologic/methods , Pneumonia, Necrotizing/diagnosis , Pneumonia, Necrotizing/drug therapy , Pneumonia, Necrotizing/microbiology , Treatment OutcomeABSTRACT
We report a rare case of Fusobacterium nucleatum necrotizing pneumonia following an influenza viral infection. This rare bacterial lung infection can have severe complications such as respiratory failure and septic shock, so early recognition and treatment are necessary.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Fusobacterium Infections/complications , Fusobacterium nucleatum/drug effects , Influenza, Human/complications , Influenza, Human/drug therapy , Pneumonia, Necrotizing/drug therapy , Pneumonia, Necrotizing/etiology , Female , Fusobacterium Infections/microbiology , Fusobacterium Infections/physiopathology , Humans , Influenza, Human/physiopathology , Middle Aged , Pneumonia, Necrotizing/physiopathology , Treatment OutcomeABSTRACT
A 37-year-old healthy man was transferred to the emergency department of this hospital because of fever and hemoptysis. A radiograph of the chest revealed a cavitary lesion in the right upper lobe. Computed tomography of the chest showed necrotizing cavitary pneumonia. Urgent throacoscopic lobectomy was performed. Sputum and intraoperative pleural pus grew methicillin resistant Staphylococcus aureus (MRSA). The pathological examination reportedly revealed cryptococcal infection. He had a full recovery after intravenous linezolid treatment.
Subject(s)
Cryptococcosis/diagnosis , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Pneumonia, Necrotizing/diagnostic imaging , Pneumonia, Staphylococcal/diagnosis , Adult , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections , Humans , Male , Methicillin-Resistant Staphylococcus aureus/drug effects , Pneumonia, Necrotizing/drug therapy , Pneumonia, Staphylococcal/drug therapy , Sputum/microbiology , Thorax/diagnostic imaging , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
We report a case of disseminated infection by Rhodococcus equi as the inaugural manifestation of idiopathic T-CD4+ lymphopenia. We aim to demonstrate our diagnostic and therapeutic approach and focus on the major dilemmas arising from the lack of scientific evidence regarding best clinical practice of this infection in humans.
Subject(s)
Actinomycetales Infections/microbiology , Lymphopenia/diagnosis , Pneumonia, Necrotizing/diagnosis , Rhodococcus equi/isolation & purification , Actinomycetales Infections/complications , Actinomycetales Infections/diagnosis , Actinomycetales Infections/pathology , Administration, Intravenous , Aged , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antibiotics, Antitubercular/administration & dosage , Antibiotics, Antitubercular/therapeutic use , Biopsy, Needle/methods , Bronchoalveolar Lavage/methods , Bronchoscopy/methods , CD4-Positive T-Lymphocytes , Cough/diagnosis , Cough/etiology , Drug Therapy, Combination , Emergency Service, Hospital , Fever/diagnosis , Fever/etiology , Humans , Levofloxacin/administration & dosage , Levofloxacin/therapeutic use , Lymphopenia/etiology , Male , Pneumonia, Necrotizing/drug therapy , Pneumonia, Necrotizing/etiology , Rifampin/administration & dosage , Rifampin/therapeutic use , Tomography, X-Ray Computed/methods , Treatment OutcomeABSTRACT
Breakthrough invasive infections occur in immunosuppressed patients while they are receiving antifungal agents for both prophylaxis and therapy. Under such conditions, unusual fungal infections emerge. Hormographiella aspergillata is considered an uncommon human pathogen and causes devastating infections. Here, we present a case report of necrotizing pneumonia caused by H. aspergillata as a breakthrough infection in a neutropenic patient and review all previous cases of H. aspergillata infection reported in the literature.
Subject(s)
Antifungal Agents , Leukemia, Myeloid, Acute , Mycoses/drug therapy , Pneumonia, Necrotizing/drug therapy , Triazoles/therapeutic use , Agaricales , Antifungal Agents/therapeutic use , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/drug therapy , Pneumonia, Necrotizing/microbiologyABSTRACT
BACKGROUND: The incidence of necrotizing pneumonia (NP) caused by Mycoplasma pneumoniae (MP) is increasing. We analyzed the clinical characteristics and the risk factors for NP caused by MP. METHODS: A retrospective observational study was conducted in 37 patients with NP caused by MP (NP group) and 74 patients diagnosed with lobar M. pneumoniae pneumonia with no necrosis (control group) who were admitted to our hospital between January 2013 and December 2017. The clinical manifestations, laboratory data, imaging findings, treatments and outcomes were analyzed. RESULTS: The proportion of females, the incidence of pleural effusion, fever duration, hospitalization days, white blood cell count, neutrophil ratio, D-dimer level and use of other types of antibiotics were higher in the NP group than in the control group (P < 0.05). The control group exhibited a greater use of low molecular weight heparin (LMWH) than the NP group (P < 0.05). According to the multivariate logistic regression analysis, a white blood cell count > 12.3 × 109/L (Odds ratio, OR = 6.412), a neutrophil ratio > 73.9% (OR = 6.081) and D-dimer level > 1367.5 ng/mL (OR = 8.501) were risk factors for pulmonary necrosis caused by MP. Furthermore, the use of LMWH (OR = 0.074) reduced the risk of pulmonary necrosis. CONCLUSIONS: NP is a rare complication of severe Mycoplasma pneumoniae pneumonia (SMPP), and although the clinical course is longer than common MP infection, the necrotic area is absorbed gradually. In patients with SMPP presenting with lobar consolidation, a white blood cell count > 12.3 × 109/L, a neutrophil ratio > 73.9% and D-dimer level > 1367.5 ng/mL are risk factors for pulmonary necrosis, and the use of LMWH reduces the risk of pulmonary necrosis.
Subject(s)
Pneumonia, Mycoplasma/complications , Pneumonia, Necrotizing/etiology , Anti-Bacterial Agents/therapeutic use , Case-Control Studies , Child , Child, Preschool , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Leukocyte Count , Male , Mycoplasma pneumoniae/pathogenicity , Pleural Effusion/drug therapy , Pleural Effusion/etiology , Pneumonia, Mycoplasma/etiology , Pneumonia, Necrotizing/drug therapy , Retrospective Studies , Risk FactorsABSTRACT
Utilization of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is expanding, but dual VA-ECMO circuits to treat cardiogenic shock with refractory hypoxemia is unreported. We describe the case of combined cardiogenic and distributive shock due to necrotizing pulmonary blastomycosis. After initial central VA-ECMO cannulation, acute respiratory distress syndrome (ARDS) with increasing shunt resulted in significant central hypoxemia due to progressive ventilation-perfusion mismatch. An additional circuit provided complete oxygenation of the high circulating volume. After 4 months on support, he underwent successful heart-lung-kidney transplantation. Dual ECMO circuits are technically feasible and may be advantageous in specific circumstances of high pulmonary shunting resulting in excessive hypoxemia unbalanced with appropriate oxygen delivery.
Subject(s)
Extracorporeal Membrane Oxygenation/methods , Hypoxia/therapy , Pneumonia, Necrotizing/complications , Shock, Cardiogenic/therapy , Adult , Amphotericin B/therapeutic use , Fatal Outcome , Humans , Hypoxia/etiology , Itraconazole/therapeutic use , Male , Pneumonia, Necrotizing/drug therapy , Shock, Cardiogenic/etiologyABSTRACT
Staphylococcus aureus is a major human pathogen that causes a wide range of infections by producing an arsenal of cytotoxins. We found that passive immunization with either a monoclonal antibody (MAb) neutralizing alpha-hemolysin or a broadly cross-reactive MAb neutralizing Panton-Valentine leukocidin, leukocidin ED, and gamma-hemolysins HlgAB and HlgCB conferred only partial protection, whereas the combination of those two MAbs conferred significant protection in a rabbit model of necrotizing pneumonia caused by the USA300 methicillin-resistant S. aureus epidemic clone.
Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Hemolysin Proteins/immunology , Leukocidins/therapeutic use , Pneumonia, Necrotizing/drug therapy , Pneumonia, Necrotizing/immunology , Acute Lung Injury/drug therapy , Acute Lung Injury/immunology , Acute Lung Injury/microbiology , Animals , Disease Models, Animal , Inflammation/drug therapy , Inflammation/immunology , Inflammation/microbiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Rabbits , Staphylococcus aureus/drug effects , Staphylococcus aureus/pathogenicityABSTRACT
Background: Necrotizing pneumonia and hyperleukocytosis, to the extent of that seen in leukaemia, is a rarely reported presentation. The commonest trigger of such a presentation is an inflammatory process caused by an overwhelming infection which leads to bone marrow irritation. However, the misdiagnosis of this clinical entity as leukaemia should be avoided at all costs so as to avoid the anxiety associated with a diagnosis of cancer, both to the patients and their families. Case presentation: Here, we report the case of a 22-month-old boy who was referred to our Pediatric Oncology Unit (POU). Owing to a high total leukocyte count (TLC) of 98,000 cells/µl, there was a strong suspicion of leukaemia. The boy had been reviewed at another hospital where he presented with fever and cough refractory to the commencement of tuberculosis medications as a result of chest radiography findings. Laboratory investigations performed on admission in the POU were negative for leukaemia and other myeloproliferative disorders. A chest computer tomography (CT) scan was performed to delineate opacification in the right middle lobe. This revealed multiple necrotic and emphysematous foci in line with a diagnosis of necrotizing pneumonia. Subsequently, the patient responded well to a course of piperacillin- tazobactam. The TLC normalized and the cough and fever resolved over a period of 2 weeks. Conclusion: Here, we describe a particularly rare case of leukaemoid reaction with a massive leukocyte count. Such patients can be easily misdiagnosed as having leukaemia or other myeloproliferative disorders, especially in settings with limited diagnostic availability. Such misdiagnosis can cause undue stress on the patient and their families. Thus, it is important that patients presenting with these symptoms should undergo a thorough review of history, physical examination and a structured workup.